Une étude épidémiologique nationale de la myasthénie en Lettonie

Verrouillé
Avatar du membre

Auteur du sujet
Pboulanger Prés.
Administrateur
Administrateur
Messages : 10762
Enregistré le : 02 févr. 2010 18:41
14
Localisation  : La Chapelle en Serval F-60520
Genre :
Zodiaque :
Âge : 67
    Windows 10 Firefox

Une étude épidémiologique nationale de la myasthénie en Lettonie

Message par Pboulanger Prés. »

:hi:

:arrow: Lu sur :https://www.ncbi.nlm.nih.gov/pubmed/29194859

[ligne][/ligne]

Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum

Image

[ligne][/ligne]

A nationwide epidemiological study of myasthenia gravis in Latvia.
Zieda A1,2, Ravina K1,3, Glazere I1, Pelcere L1, Naudina MS1, Liepina L4, Kamsa I1, Kurjane N5, Woodhall M6, Jacobson L6, Leite MI6, Tandon K6, Kenina V4.
Eur J Neurol. 2017 Nov 30. doi: 10.1111/ene.13535.


Abstract

  • BACKGROUND AND PURPOSE:

    Myasthenia gravis (MG) is an autoimmune disorder characterized by fatigable muscle weakness due to of antibody-mediated impairment of neuromuscular transmission. The aim of this study was to investigate the incidence and prevalence of MG in Latvia, and to characterize this population by well-established clinical parameters such as age at onset, presence of associated antibodies, and thymus pathology.
  • METHODS:

    cases of patients with known MG or presenting with first MG symptoms within the time period from 1 January 2010 to 31 December 2014 were selected from the database of the Neuromuscular Disease Clinic of Pauls Stradins Clinical University Hospital and Children's Clinical University Hospital. Crude rates were calculated based on population data. These were directly age-standardized to the European and WHO world standard populations. The analysis of clinical characteristics was carried out in a cohort of patients who had undergone complete set of electrophysiological, serological and radiological investigations (n=153; 68%).
  • RESULTS:

    During the study period 99 incident and 226 prevalent cases were identified. The total crude MG incidence was 9.7 per million person-years. The prevalence of MG on January 1, 2015 was 113.8 per million. 54.2% of patients tested positive for AChR antibodies, 7.8% for MusK antibodies, and 1.3% for LRP4 antibodies.
  • CONCLUSIONS:

    This is the first study of MG in Latvia and the second population-based study of MG in the Eastern Europe. Our epidemiologic results are similar to those in some other European and Northern American countries, and show high prevalence and increasing incidence of late-onset MG.


Lien direct vers Google traduction
https://translate.google.fr/translate?s ... t=&act=url
Message d' un membre de l'équipe technique
Nous utilisons un service automatique de traduction fourni par YANDEX.
Soyez vigilant sur le risque de contre-sens inhérent à ce genre d'outils.
Amicalement,
Image
Verrouillé

Retourner vers « 2017 »